vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Piedmont Realty Trust, Inc. (PDM). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $143.3M, roughly 1.2× Piedmont Realty Trust, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 0.4%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 0.0%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
ESPR vs PDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $143.3M |
| Net Profit | — | $-45.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | -31.4% |
| Revenue YoY | 143.7% | 0.4% |
| Net Profit YoY | — | -27.9% |
| EPS (diluted) | $0.32 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $143.3M | ||
| Q4 25 | $168.4M | $142.9M | ||
| Q3 25 | $87.3M | $139.2M | ||
| Q2 25 | $82.4M | $140.3M | ||
| Q1 25 | $65.0M | $142.7M | ||
| Q4 24 | $69.1M | $143.2M | ||
| Q3 24 | $51.6M | $139.3M | ||
| Q2 24 | $73.8M | $143.3M |
| Q1 26 | — | $-45.0M | ||
| Q4 25 | — | $-43.2M | ||
| Q3 25 | $-31.3M | $-13.5M | ||
| Q2 25 | $-12.7M | $-16.8M | ||
| Q1 25 | $-40.5M | $-10.1M | ||
| Q4 24 | — | $-30.0M | ||
| Q3 24 | $-29.5M | $-11.5M | ||
| Q2 24 | $-61.9M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — |
| Q1 26 | — | -31.4% | ||
| Q4 25 | — | -30.3% | ||
| Q3 25 | -35.9% | -9.7% | ||
| Q2 25 | -15.4% | -12.0% | ||
| Q1 25 | -62.2% | -7.1% | ||
| Q4 24 | — | -20.9% | ||
| Q3 24 | -57.2% | -8.3% | ||
| Q2 24 | -83.9% | -6.8% |
| Q1 26 | — | $-0.10 | ||
| Q4 25 | $0.32 | $-0.34 | ||
| Q3 25 | $-0.16 | $-0.11 | ||
| Q2 25 | $-0.06 | $-0.14 | ||
| Q1 25 | $-0.21 | $-0.08 | ||
| Q4 24 | $-0.14 | $-0.25 | ||
| Q3 24 | $-0.15 | $-0.09 | ||
| Q2 24 | $-0.33 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $2.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.5B |
| Total Assets | $465.9M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.3M | ||
| Q4 25 | $167.9M | $731.0K | ||
| Q3 25 | $92.4M | $3.0M | ||
| Q2 25 | $86.1M | $3.3M | ||
| Q1 25 | $114.6M | $2.9M | ||
| Q4 24 | $144.8M | $109.6M | ||
| Q3 24 | $144.7M | $133.6M | ||
| Q2 24 | $189.3M | $138.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $-302.0M | $1.5B | ||
| Q3 25 | $-451.4M | $1.5B | ||
| Q2 25 | $-433.5M | $1.5B | ||
| Q1 25 | $-426.2M | $1.6B | ||
| Q4 24 | $-388.7M | $1.6B | ||
| Q3 24 | $-370.2M | $1.6B | ||
| Q2 24 | $-344.2M | $1.7B |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $465.9M | $4.0B | ||
| Q3 25 | $364.0M | $4.0B | ||
| Q2 25 | $347.1M | $4.0B | ||
| Q1 25 | $324.0M | $4.0B | ||
| Q4 24 | $343.8M | $4.1B | ||
| Q3 24 | $314.1M | $4.1B | ||
| Q2 24 | $352.3M | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.49× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 1.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 110.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $140.6M | ||
| Q3 25 | $-4.3M | $35.8M | ||
| Q2 25 | $-31.4M | $50.1M | ||
| Q1 25 | $-22.6M | $3.7M | ||
| Q4 24 | $-35.0M | $198.1M | ||
| Q3 24 | $-35.3M | $42.9M | ||
| Q2 24 | $-7.2M | $66.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — |
| Q1 26 | — | 110.3% | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PDM
Segment breakdown not available.
